Mesoblast talks development of cell-based medicines

0
212



22 Mar 2016 – Mesoblast Limited (ASX:MSB) CEO Professor Silviu Itescu discusses the company’s latest trial results and near-term value inflexion points at the ASX CEO Sessions in Sydney.

LEAVE A REPLY

Please enter your comment!
Please enter your name here